Hepatitis E
Hepatitis E | |
---|---|
Infectious disease, Hepatology | |
Symptoms | Nausea, jaundice[1] |
Complications | Liver failure[1] |
Causes | Hepatitis E virus (HEV)[1] |
Diagnostic method | Blood test[1] |
Differential diagnosis | Hepatitis A[2] |
Treatment | Rest, ribavirin (if chronic)[1] |
Frequency | 28 million worldwide (2013)[3] |
Hepatitis E is inflammation of the liver caused by
Like hepatitis A, hepatitis E usually follows an acute and
In 2017, hepatitis E was estimated to affect more than 19 million people.
The virus was discovered in 1983 by researchers investigating an outbreak of unexplained hepatitis among Soviet soldiers serving in Afghanistan.[17] The earliest well-documented epidemic of hepatitis E occurred in 1955 in New Delhi and affected tens of thousands of people (hepatitis E virus was identified as the etiological agent at fault retrospectively through testing of stored samples).[19]
Signs and symptoms
Acute infection
The average
Chronic infection
While usually lasting weeks and then resolving, in people with
Other organs
Infection with hepatitis E virus can also lead to problems in other organs. For some of these reported conditions such as musculoskeletal or immune-mediated manifestations the relationship is not entirely clear, but for several neurological and blood conditions the relationship appears more consistent:[27][28][29][30]
- Acute pancreatitis (HEV genotype 1[5])
- Neurological complications (though the mechanism of neurological damage is unknown at this point.Guillain-Barré syndrome (acute limb weakness due to nerve involvement), neuralgic amyotrophy (arm and shoulder weakness, also known as Parsonage-Turner syndrome), acute transverse myelitis and acute meningoencephalitis.
- Glomerulonephritis with nephrotic syndrome and/or cryoglobulinemia
- Mixed cryoglobulinemia, where antibodies in the bloodstream react inappropriately at low temperatures
- Severe thrombocytopenia (low platelet count in the blood) which confers an increased risk of dangerous bleeding
Infection in pregnancy
Pregnant women show a more severe course of infection than other populations. Liver failure with mortality rates of 20% to 25% has been reported from outbreaks of genotype 1 and 2 HEV in developing countries. Besides signs of an acute infections, adverse effects on the mother and fetus may include
The pathological and biological mechanisms behind the adverse outcomes of pregnancy infections remain largely unclear. Increased viral replication and influence of hormonal changes on the immune system are currently thought to contribute to worsening the course of infection.[33] Furthermore, studies showing evidence for viral replication in the placenta or reporting the full viral life cycle in placental-derived cells in vitro suggest that the human placenta may be a site of viral replication outside the liver.[34] The primary reason for HEV severity in pregnancy remains enigmatic.[17]
Virology
Classification
HEV is classified into the family Hepeviridae, which is divided in two genera, Orthohepevirus (all mammalian and avian HEV isolates) and Piscihepevirus (cutthroat trout HEV).[33] Only one serotype of the human virus is known, and classification is based on the nucleotide sequences of the genome.[35] Genotype 1 can be further subclassified into five subtypes,[36] genotype 2 into two subtypes,[37] and genotypes 3 and 4 have been divided into 10[38] and seven subtypes.[38] Additionally there are genotypes 5, 6, 7 and 8.[16] Rat HEV was first isolated from Norway rats in Germany,[39] and a 2018 CDC article indicated the detection of rat HEV RNA in a transplant recipient.[40]
Distribution
- Genotype 1 has been isolated from tropical and several subtropical countries in Asia and Africa.[41]
- Genotype 2 has been isolated from Mexico, Nigeria, and Chad.[42]
- Genotype 3 has been isolated almost worldwide including Asia, Europe, Oceania, and North and South America.[43]
- Genotype 4 appears to be limited to Asia and indigenous cases from Europe.[41][44]
Genotypes 1 and 2 are restricted to humans and often associated with large outbreaks and epidemics in developing countries with poor sanitation conditions.[41] Genotypes 3 and 4 infect humans, pigs, and other animal species and have been responsible for sporadic cases of hepatitis E in both developing and industrialized countries.[45][46]
Transmission
Hepatitis E (genotype 1 and, to a lesser extent genotype 2) is endemic and can cause outbreaks in Southeast Asia, northern and central Africa, India, and Central America.[5][48] It is spread mainly by the fecal–oral route due to contamination of water supplies or food; direct person-to-person transmission is uncommon.[5][21] In contrast to genotypes 1 and 2, genotypes 3 and 4 cause sporadic cases thought to be contracted zoonotically, from direct contact with animals or indirectly from contaminated water or undercooked meat.[5][49]
Outbreaks of epidemic hepatitis E most commonly occur after heavy rainfalls, especially
According to the Department for Environment, Food and Rural Affairs, evidence indicated the increase in hepatitis E in the U.K. was due to food-borne
Hepatitis E infection appeared to be more common in people on hemodialysis, although the specific risk factors for transmission are not clear.[60]
Animal reservoir
Hepatitis E due to genotypes other than 1 and 2 is thought to be a zoonosis, in that animals are thought to be the primary reservoir; deer and swine have frequently been implicated.[61] Domestic animals have been reported as a reservoir for the hepatitis E virus, with some surveys showing infection rates exceeding 95% among domestic pigs.[62] Replicative virus has been found in the
A number of other small mammals have been identified as potential reservoirs: the lesser bandicoot rat (
Genomics
HEV has three open reading frames (ORFs) encoding two polyproteins (O1 and O2 protein). ORF2 encodes three capsid proteins whereas O1 encodes seven fragments involved in viral replication, among others.[66][67][68]
The smallest ORF of the HEV genome, ORF3 is translated from a subgenomic RNA into O3, a protein of 113–115 amino acids. ORF3 is proposed to play critical roles in immune evasion by HEV. Previous studies showed that ORF3 is bound to viral particles found in patient sera and produced in cell culture. Although in cultured cells ORF3 has not appeared essential for HEV RNA replication, viral assembly, or infection, it is required for particle release.[69]
Virus lifecycle
The lifecycle of hepatitis E virus is unknown; the capsid protein obtains viral entry by binding to a cellular receptor. ORF2 (c-terminal) moderates viral entry by binding to HSC70.[70][71]
Geldanamycin blocks the transport of HEV239 capsid protein, but not the binding/entry of the truncated capsid protein, which indicates that Hsp90 plays an important part in HEV transport.[70]
Diagnosis
In terms of the diagnosis of hepatitis E, only a laboratory blood test that confirms the presence of HEV RNA or IgM antibodies to HEV can be trusted.[11][72] In the United States no serologic tests for diagnosis of HEV infection have ever been authorized by the Food and Drug Administration.[11] The World Health Organization has developed an international standard strain for detection and quantification of HEV RNA.[73] In acute infection the viremic window for detection of HEV RNA closes 3 weeks after symptoms begin.[74]
Virological markers
Assuming that vaccination has not occurred, tests may show:[5]
- if the person's immune system is normal, then
- if IgM anti-HEV is negative, then there is no evidence of recent HEV infection
- if IgM anti-HEV is positive, then the person is likely to have a recent or current HEV infection
- if the person's immune system is weakened by disease or medical treatment, as in the case of a person who has received a solid organ transplant, then
- if IgM anti-HEV is negative, then if additional blood testing reveals
- positive HEV RNA then the person has HEV infection
- negative HEV RNA then there is no evidence of current or recent infection
- if IgM anti-HEV is positive, then the person is likely to have a recent or current HEV infection, and HEV RNA may be useful to track resolution
- if IgM anti-HEV is negative, then if additional blood testing reveals
Prevention
Sanitation
Sanitation is the most important measure in prevention of hepatitis E; this consists of proper treatment and disposal of human waste, higher standards for public water supplies, improved personal hygiene procedures, and sanitary food preparation. Thus, prevention strategies of this disease are similar to those of many other diseases that plague developing nations.[21] Cooking meat at 71 °C (159.8 °F) for five minutes kills the hepatitis E virus, different temperatures means different time to inactivate the virus.[59]
Blood products
The amount of virus present in blood products required to cause transfusion-transmitted infection (TTI) appears variable. Transfusion transmission of hepatitis E virus can be screened via minipool HEV NAT (Nucleic acid testing) screening.[75][76] NAT is a technique used to screen blood molecularly, when blood donations are received; it screens for TTI.[77]
Vaccines
A vaccine based on recombinant viral proteins was developed in the 1990s and tested in a high-risk population (in Nepal) in 2001.[78] The vaccine appeared to be effective and safe, but development was stopped for lack of profitability, since hepatitis E is rare in developed countries.[79] No hepatitis E vaccine is licensed for use in the United States.[11]
The exception is China; after more than a year of scrutiny and inspection by China's State Food and Drug Administration (SFDA), a hepatitis E vaccine developed by Chinese scientists was available at the end of 2012. The vaccine—called HEV 239 by its developer Xiamen Innovax Biotech—was approved for prevention of hepatitis E in 2012 by the Chinese Ministry of Science and Technology, following a controlled trial on 100,000+ people from Jiangsu Province where none of those vaccinated became infected during a 12-month period, compared to 15 in the group given placebo.[80] The first vaccine batches came out of Innovax's factory in late October 2012, to be sold to Chinese distributors.[79]
Due to lack of evidence, the World Health Organization has not made a recommendation regarding routine use of the HEV 239 vaccine as of 2015.[81] Its 2015 position was that national authorities may decide to use the vaccine based on their local epidemiology.[81]
Treatment
There is no drug that has established safety and effectiveness for hepatitis E, and there have been no large randomized clinical trials of antiviral drugs.[8] Reviews of existing small studies suggest that ribavirin can be considered effective in immunocompromised people who have developed chronic infection.[82][83]
Chronic HEV infection is associated with immunosuppressive therapies, and when that happens in individuals with solid-organ transplantation, reducing immunosuppressive medications can result in clearance of HEV in one third of patients.[5]
Epidemiology
The hepatitis E virus causes around 20 million infections a year. These result in around three million acute illnesses and resulted in 44,000 deaths during 2015.
Recent outbreaks
In October 2007, an epidemic of hepatitis E occurred in
In July 2012, an outbreak was reported in South Sudanese refugee camps in
During an outbreak in Namibia, the number of affected people rose from 490 in January 2018, to 5014 (with 42 deaths) by April 2019, to 6151 cases (with 56 deaths) by August 2019; the WHO estimated that the case fatality rate was 0.9%.[91][92][93]
In Hong Kong in May 2020, there were at least 10 cases of hepatitis E that were transmitted by rats, and possibly hundreds of cases that had a transmission mechanism that is not fully understood.[94]
2024 outbreak in Finland. A record number of hepatitis E cases have been diagnosed in Finland so far this year, according to figures released on Tuesday by public health authority THL. Data from the authority's Infectious Diseases Register showed that a total of 92 lab-confirmed infections have been recorded since the beginning of January until 12 March, with 42 people requiring hospital treatment. The outbreak has been suspected to be caused by a batch of mettwurst that has been recalled. [95]
Evolution
The strains of HEV that exist today may have arisen from a shared ancestor virus 536 to 1344 years ago.[96]
Another analysis has dated the origin of Hepatitis E to ~6000 years ago, with a suggestion that this was associated with domestication of pigs.
Whereas genotype 2 remains less commonly detected than other genotypes, genetic evolutionary analyses suggest that genotypes 1, 3, and 4 have spread substantially during the past 100 years.[17]
References
This article incorporates public domain text from the CDC as cited
- ^ a b c d e "Hepatitis E | NIDDK". National Institute of Diabetes and Digestive and Kidney Diseases. Retrieved 24 June 2018.
- ^ "Hepatitis A Differential Diagnoses". emedicine.medscape.com. Retrieved 27 July 2019.
- ^ PMID 30496104.
- ^ "Hepatitis E: Background, Etiopathophysiology, Epidemiology". medscape.com. Medscape. 2019.
- ^ PMID 24396139.
- ^ "Hepatitis (Viral) NIDDK". The National Institute of Diabetes and Digestive and Kidney Diseases. Retrieved 2020-06-19.
- ^ "What is hepatitis?". www.who.int. WHO. Retrieved 17 April 2019.
- ^ a b c d e "Hepatitis E". www.who.int. WHO. Retrieved 17 April 2019.
- ISBN 978-1-118-97355-4.
- ^ S2CID 44504380.
- ^ a b c d "Hepatitis E Questions and Answers for Health Professionals". www.cdc.gov. CDC. 13 June 2018.
- S2CID 41424447.)
{{cite journal}}
: CS1 maint: multiple names: authors list (link - PMID 25755487.
- S2CID 19917145.
- PMID 29609832.
- ^ PMID 28425927.
- ^ PMID 24396139.
- PMID 25714510.
- PMID 23313154.
- ISBN 978-0-323-41742-6.
- ^ a b c "Hepatitis E Fact sheet". WHO. Retrieved 17 April 2019.
- ^ S2CID 32198953.
- ^ "Facts about hepatitis E". ecdc.europa.eu. European Centre for Disease Prevention and Control. 30 March 2017. Retrieved 17 April 2019.
- PMID 22405325.
- PMID 25195557.
- PMID 29735575.
- PMID 26358655.
- PMID 30072282.
- PMID 21291585.
- S2CID 25495184.
- S2CID 72665101.)
{{cite journal}}
: CS1 maint: multiple names: authors list (link - PMID 27657112.
- ^ S2CID 44761962.
- PMID 24622580.
- ISBN 978-1-4377-2767-8. Retrieved 27 June 2020.
- ISBN 978-94-024-0942-0.
- ISBN 978-94-024-0942-0.
- ^ ISBN 978-1-4377-0881-3.
- PMID 20735931.
- PMID 30457530.
- ^ PMID 21149996.
- PMID 22460217.)
{{cite journal}}
: CS1 maint: DOI inactive as of March 2024 (link - ^ Hepatitis E Vaccine Working Group (1 October 2014). Recommendations of HEV Working Group on the use of hepatitis E vaccine (PDF). www.who.int (Report). WHO.
- ISBN 978-1-4377-3777-6.
- PMID 19361937.
- S2CID 207050371.
- PMID 23347828.
- ISBN 978-1-4398-1237-2.
- PMID 23965731.
- ISBN 978-1-4614-5719-0.
- ISBN 978-0-12-381507-1.
- PMID 16705572.
- ^ ISBN 978-0-471-71791-1.
- ISBN 978-90-481-9657-9.
- PMID 21320558.
- PMID 15757573.
- S2CID 25571762.
- ^ Doward, Jamie (21 September 2013). "Chefs fight for the right to serve their pork pink". The Observer newspaper.
- ^ a b "Hepatitis E Virus and Food". www.fsai.ie. Food Safety Authority of Ireland. 11 July 2017. Archived from the original on 28 May 2019. Retrieved 27 July 2019.
- S2CID 24480333.
- PMID 20359452.
- PMID 17493260.
- PMID 16485490.
- PMID 18983247.
- PMID 19889929.)
{{cite journal}}
: CS1 maint: multiple names: authors list (link - ISBN 978-93-5250-190-8. Retrieved 22 July 2019.
- PMID 31000788.
- PMID 21345356.
- PMID 28096411.
- ^ PMID 26038426.
- PMID 19622744.
- S2CID 11958858.subscription needed
- PMID 23647659.
- PMID 30984394.
- ISBN 978-0-08-092230-0.
- PMID 29450199.
- PMID 24678164.
- PMID 17329696.
- ^ PMID 23128204.
- PMID 22931753.
- ^ PMID 25935931.
- S2CID 25304902.
- S2CID 10199788.
- ^ Teshale EH (31 May 2017). "Hepatitis E – Infectious Diseases Related to Travel Chapter 3 – 2018 Yellow Book". www.cdc.gov. CDC.
- PMID 18662274.
- ^ Public Health England ir. "Common animal associated infections quarterly report (England and Wales) – fourth quarter 2015" (PDF). gov.uk. Retrieved 27 July 2019.
- ^ PMID 20031058.
- ^ Investigation of Hepatitis E Outbreak Among Refugees — Upper Nile, South Sudan, 2012–2013. www.cdc.gov (Report). Vol. 62. CDC Morbidity and Mortality Weekly Report. 26 July 2013. pp. 581–586.
- ^ Hereward Holland (2 February 2013). "Hepatitis outbreak kills 88 in South Sudan—aid agency". Reuters.
- ^ Sharma C (5 September 2014). "Nepal, hepatitis E epidemic: 9 dead and over 6 thousand infected". www.asianews.it.
- ^ "Hepatitis E cases in Namibia rise to 490". www.xinhuanet.com. Xinhua News. 28 January 2018. Archived from the original on January 29, 2018.
- ^ "Weekly bulletins on outbreaks and other emergencies" (PDF). World Health Organization. WHO.int. Retrieved 20 May 2019.
- ^ "Outbreaks and Emergencies Bulletin, Week 33: 12 – 18 August 2019". WHO | Regional Office for Africa. Retrieved 20 August 2019.
- ^ Jessie Yeung (8 May 2020). "Rats are infecting humans with hepatitis, and nobody knows how". CNN. Retrieved 11 May 2020.
- ^ "THL: Finland faces hepatitis E epidemic with record number of cases". YLE. 12 March 2024. Retrieved 13 March 2024.
- PMID 21203540.
- PMID 31664890.
- PMID 27264728.)
{{cite journal}}
: CS1 maint: multiple names: authors list (link
This article was submitted to WikiJournal of Medicine for external academic peer review in 2018 (reviewer reports). The updated content was reintegrated into the Wikipedia page under a CC-BY-SA-3.0 license (2019). The version of record as reviewed is:
Osmin Anis, et al. (27 July 2019). "Hepatitis E". WikiJournal of Medicine. 6 (1): 3. {{cite journal}}
: CS1 maint: unflagged free DOI (link
Further reading
- Parvez MK (2013-01-01). "Chronic hepatitis E infection: risks and controls". Intervirology. 56 (4): 213–216. PMID 23689166.
- Aggarwa R, Gandhi S (2010). "A systematic review on prevalence of hepatitis E disease and seroprevalence of hepatitis E virus antibody" (PDF). World Health Organization. WHO/IVB/10.14.